Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001931309 | SCV002197541 | uncertain significance | Hereditary breast ovarian cancer syndrome | 2021-09-02 | criteria provided, single submitter | clinical testing | |
University of Washington Department of Laboratory Medicine, |
RCV003156870 | SCV003847543 | likely benign | Hereditary cancer-predisposing syndrome | 2023-03-23 | criteria provided, single submitter | curation | Missense variant in a coldspot region where missense variants are very unlikely to be pathogenic (PMID:31911673). |
Ambry Genetics | RCV003156870 | SCV005548758 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-09-10 | criteria provided, single submitter | clinical testing | The c.6513_6514delGTinsCC variant (also known as p.S2172P), located in coding exon 10 of the BRCA2 gene, results from an in-frame deletion of GT and insertion of CC at nucleotide positions 6513 to 6514. This results in the substitution of the serine residue for a proline residue at codon 2172, an amino acid with similar properties. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be neutral by in silico analysis (Choi Y et al. PLoS ONE. 2012; 7(10):e46688). Based on the available evidence, the clinical significance of this variant remains unclear. |